Dental implant surgery,an established practice,has been widely used in patients with dentition defect.Dental implanta-tion-induced osteomyelitis of the jaw is a rare complication.Osteomyelitis of the jaw is an inflammatory change of the jaw caused by bac-terial infection or other physical and chemical factors involving the whole bone tissue,such as periosteum,blood vessels and nerves in the medullary cavity,etc.Due to protracted course and complicated treatment of the disease,the consequences will be serious if not swiftly managed.Here,an unusual case of severe mandibular osteomyelitis following mandibular implant surgery is reported.Also,re-lated literature is reviewed to elucidate the clinical characteristics and management as to highlight the understanding of this complication and provide reference for clinical prevention,diagnosis and treatment.

Objective:To evaluate the efficacy and safety of nebulized inhalation of recombinant human interferon (IFN) α1b injection in the treatment of respiratory syncytial virus (RSV) associated lower respiratory tract infections (pneumonia and bronchiolitis) in children.Methods:A randomized, double-blind, parallel, placebo-controlled add-on design was used.Children with pneumonia or bronchiolitis aged 2 months to 5 years who tested positive for RSV antigen within 72 hours of onset from 30 clinical trial sites including Beijing Children′s Hospital, Capital Medical University between February 2021 and December 2022 were included in this study and randomly divided into 2 groups at a ratio of 1∶1 based on a stratified-block method.Both groups received basic treatments such as cough control, asthma relieving, expectorant treatment, fever reduction, oxygen therapy, etc.The experimental group received additional nebulized inhalation of IFN α1b injection at a dose of 2.0 μg/(kg·time), twice a day.The control group received nebulized inhalation of placebo twice a day.Clinical efficacy was evaluated based on indicators such as the duration of clinical symptoms and signs, and the Kaplan-Meier method was used to calculate the median and 95% CI of the duration of clinical symptoms and signs.The Log-rank test was used to compared data between groups.Safety was assessed through the incidence of adverse reactions and laboratory tests, and the Chi-square test was used to analyze the difference between groups. Results:There were 123 children in the experimental group and 122 children in the control group.The median durations of all the 5 clinical symptoms and signs [including shortness of breath, wheezing, dyspnea (visible retractions), decreased transcutaneous oxygen saturation, and abnormal mental state] in the experimental group after treatment were slightly shortened than those in the control group [2.7 d(95% CI: 1.9-3.0 d)] vs.[2.9 d(95% CI: 2.6-3.6 d), P=0.027].The improvement in dyspnea (retractions) was especially pronounced in the experimental group, with a relief rate of 50.0% (0, 100%) on the first day of administration[compared with 0 (0, 50.0%) in the control group ( Z=2.002, P=0.025)].The median duration of dyspnea in the experimental group was nearly 1 day shorter than that in the control group [1.0 d(95% CI: 0.7-1.7 d) vs.1.8 d(95% CI: 1.0-2.5 d), P=0.046].There were no significant difference in hospital stay [6.0(5.0, 8.0) d vs.6.5(5.0, 8.0) d, Z=0.675, P=0.500], oxygen therapy duration [32.0(14.0, 96.3) h vs.39.0 (24.0, 83.2) h, Z=0.094, P=0.925], the recovery rate from clinical symptoms during treatment [(105/106, 99.1%) vs.(96/101, 95.0%)], and recurrence rate [(0/106, 0) vs.(2/101, 2.0%)] between the 2 groups (all P>0.05).However, the above-mentioned four indicators in the experimental group showed a trend of clinical benefits.The quantitative virus detection results showed that the RSV viral load in both groups decreased after treatment compared to before treatment.After 2 days of treatment, the decline rate of RSV viral load from the baseline was 0.90 lg copies/(mL·d) in the experimental group and 0.25 lg copies/(mL·d)in the control group, with a statistically significant difference ( P<0.05).Furthermore, there was no statistically significant difference in the incidence of adverse reactions between the 2 groups ( P>0.05).Importantly, no drug-related serious adverse reactions occurred in both groups. Conclusions:The nebulized inhalation therapy of IFN α1b demonstrates efficacy and safety in treating pediatric RSV associated lower respiratory tract infections.It particularly offers outstanding clinical therapeutic value for severe children.

Dental implant surgery,an established practice,has been widely used in patients with dentition defect.Dental implanta-tion-induced osteomyelitis of the jaw is a rare complication.Osteomyelitis of the jaw is an inflammatory change of the jaw caused by bac-terial infection or other physical and chemical factors involving the whole bone tissue,such as periosteum,blood vessels and nerves in the medullary cavity,etc.Due to protracted course and complicated treatment of the disease,the consequences will be serious if not swiftly managed.Here,an unusual case of severe mandibular osteomyelitis following mandibular implant surgery is reported.Also,re-lated literature is reviewed to elucidate the clinical characteristics and management as to highlight the understanding of this complication and provide reference for clinical prevention,diagnosis and treatment.

Objective:To evaluate the efficacy and safety of nebulized inhalation of recombinant human interferon (IFN) α1b injection in the treatment of respiratory syncytial virus (RSV) associated lower respiratory tract infections (pneumonia and bronchiolitis) in children.Methods:A randomized, double-blind, parallel, placebo-controlled add-on design was used.Children with pneumonia or bronchiolitis aged 2 months to 5 years who tested positive for RSV antigen within 72 hours of onset from 30 clinical trial sites including Beijing Children′s Hospital, Capital Medical University between February 2021 and December 2022 were included in this study and randomly divided into 2 groups at a ratio of 1∶1 based on a stratified-block method.Both groups received basic treatments such as cough control, asthma relieving, expectorant treatment, fever reduction, oxygen therapy, etc.The experimental group received additional nebulized inhalation of IFN α1b injection at a dose of 2.0 μg/(kg·time), twice a day.The control group received nebulized inhalation of placebo twice a day.Clinical efficacy was evaluated based on indicators such as the duration of clinical symptoms and signs, and the Kaplan-Meier method was used to calculate the median and 95% CI of the duration of clinical symptoms and signs.The Log-rank test was used to compared data between groups.Safety was assessed through the incidence of adverse reactions and laboratory tests, and the Chi-square test was used to analyze the difference between groups. Results:There were 123 children in the experimental group and 122 children in the control group.The median durations of all the 5 clinical symptoms and signs [including shortness of breath, wheezing, dyspnea (visible retractions), decreased transcutaneous oxygen saturation, and abnormal mental state] in the experimental group after treatment were slightly shortened than those in the control group [2.7 d(95% CI: 1.9-3.0 d)] vs.[2.9 d(95% CI: 2.6-3.6 d), P=0.027].The improvement in dyspnea (retractions) was especially pronounced in the experimental group, with a relief rate of 50.0% (0, 100%) on the first day of administration[compared with 0 (0, 50.0%) in the control group ( Z=2.002, P=0.025)].The median duration of dyspnea in the experimental group was nearly 1 day shorter than that in the control group [1.0 d(95% CI: 0.7-1.7 d) vs.1.8 d(95% CI: 1.0-2.5 d), P=0.046].There were no significant difference in hospital stay [6.0(5.0, 8.0) d vs.6.5(5.0, 8.0) d, Z=0.675, P=0.500], oxygen therapy duration [32.0(14.0, 96.3) h vs.39.0 (24.0, 83.2) h, Z=0.094, P=0.925], the recovery rate from clinical symptoms during treatment [(105/106, 99.1%) vs.(96/101, 95.0%)], and recurrence rate [(0/106, 0) vs.(2/101, 2.0%)] between the 2 groups (all P>0.05).However, the above-mentioned four indicators in the experimental group showed a trend of clinical benefits.The quantitative virus detection results showed that the RSV viral load in both groups decreased after treatment compared to before treatment.After 2 days of treatment, the decline rate of RSV viral load from the baseline was 0.90 lg copies/(mL·d) in the experimental group and 0.25 lg copies/(mL·d)in the control group, with a statistically significant difference ( P<0.05).Furthermore, there was no statistically significant difference in the incidence of adverse reactions between the 2 groups ( P>0.05).Importantly, no drug-related serious adverse reactions occurred in both groups. Conclusions:The nebulized inhalation therapy of IFN α1b demonstrates efficacy and safety in treating pediatric RSV associated lower respiratory tract infections.It particularly offers outstanding clinical therapeutic value for severe children.

Objective To explore the diagnostic value of long non-coding RNA nuclear-enriched abundant transcript 1(LncRNA NEATl)and microRNA(miR)-424-5p in the diagnosis of endometriosis(EM)combined with infertility and its application value in disease staging.Methods A total of 232 EM patients who visited Shijiazhuang Maternal and Child Health Hospital from October 2021 to October 2023 were selected as the study subjects,120 patients with EM combined with infertility were used as the infertility group,and 112 patients with pure EM were regarded as the control group.The infertility group was separated into r-AFS stages Ⅰ～Ⅱ(n=27),r-AFS stage Ⅲ(n=45),and r-AFS stage Ⅳ(n=48)according to the American r-AFS staging standards,and qRT-PCR method was applied to detect the expression levels of serum LncRNA NEAT1 and miR-424-5p.Receiver operating characteristic(ROC)curve was applied to analyze the value of serum LncRNA NEAT1 and miR-424-5p in diagnosing EM combined with infertility,and multivariate Logistic regression was applied to analyze the influencing factors of EM combined with infertility.Bioinformatics analysis of LncRNA NEAT1 targeting miR-424-5p was performed on the TargetScanHuman website.Pearson method was applied to analyze the correlation between serum LncRNA NEAT1 and miR-424-5p expression levels in patients with EM combined with infertility.Results Differences of serum LncRNA NEAT1(1.16±0.15 vs 1.02±0.13),pelvic surgery history ratio(17.50％vs 1.79％),miR-424-5p(0.92±0.11 vs 1.04±0.12)expression levels between infertility group and control group were significant,and the differences were significant(t=7.753,16.018,7.974,all P＜0.05).Serum LncRNA NEAT1(1.05±0.10,1.14±0.14,1.24±0.19)increased and miR-424-5p(0.99±0.12,0.93±0.11,0.87±0.10)decreased in r-AFS stage Ⅰ～Ⅱ,Ⅲ,Ⅳ patients,and the differences were significant(F=13.528,10.910,all P＜0.05).There was a targeting relationship between LncRNA NEAT1 and miR-424-5p,and there was a negative correlation between serum LncRNA NEAT1 and miR-424-5p expression levels in EM patients with infertility(r=-0.431,P＜0.05).The AUCs of serum LncRNANEAT1,miR-424-5p,and combined diagnosis for EM combined with infertility were 0.782,0.719 and 0.835,respectively,and the AUC of combined diagnosis was better than that of individual detection(Z=2.625,3.861,P=0.009,0.001).LncRNA NEAT1 was a risk factor for EM combined with infertility,while miR-424-5p was a protective factor(all P＜0.05).Conclusion The expression level of serum LncRNA NEAT1 is increased and miR-424-5p is decreased in EM patients with infertility,both of which are related to the disease stage and the occurrence of infertility.